Axovant Sciences Ltd. Common Sh (AXON) 15.28 $AXON
Post# of 273322
Posted On: 09/26/2016 1:01:59 AM
Axovant Sciences Ltd. Common Sh (AXON) 15.28 $AXON
Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease
PR Newswire - Wed Sep 21, 7:00AM CDT
Memory evaluations are critical to the early diagnosis and effective treatment of people with Alzheimer's disease, according to Dr. Gary Small, director of geriatric psychiatry at UCLA's Semel Institute for Neuroscience and Human Behavior.
AXON: 15.28 (+0.14)
Axovant Sciences to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Sep 06, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Morgan Stanley Global Healthcare Conference on September 13 at 5:15 p.m. EDT.
AXON: 15.28 (+0.14), MS: 31.91 (-0.33)
Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Baird 2016 Global Healthcare Conference on September 7 at 10:50 a.m. EDT.
AXON: 15.28 (+0.14)
Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.28 (+0.14), GSK: 43.42 (-0.16)
Axovant Sciences Announces 2015 Fiscal Year-End Financial Results and Corporate Updates
PR Newswire - Mon Jun 06, 7:00AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today reported financial results for the fourth fiscal quarter and twelve months ended March 31, 2016.
AXON: 15.28 (+0.14)
Global Lewy Body Dementia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Axovant Sciences, BioArctic Neuroscience, Immungenetics - Research and Markets
BusinessWire - Mon May 16, 10:43AM CDT
Research and Markets has announced the addition of the "Lewy body Dementia - Pipeline Review, H1 2016" report to their offering.
AXON: 15.28 (+0.14)
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 15.28 (+0.14), BMRN: 97.40 (-0.05), PFE: 34.26 (+0.11)
Should You Buy Axovant Sciences (AXON) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:35AM CDT
Axovant Sciences (AXON) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
AXON: 15.28 (+0.14)
Drug Stocks Reporting Earnings on May 17: AXON & FWP
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:31AM CDT
Quite a few beats and some misses. That's how the first-quarter scorecard cycle looks like as the earnings season nears its end for 10 of the 16 Zacks sectors.
AXON: 15.28 (+0.14), ABT: 42.19 (-0.03), JNJ: 118.81 (-0.65), FWP: 20.21 (+0.26), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), NVS: 81.48 (-0.55)
Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors
PR Newswire - Fri May 13, 5:59AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced Gary P. Pisano has joined its Board of Directors and will also serve as a member of the Board's Audit Committee. Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School and has been on the Harvard faculty since 1988. His work has focused on a wide range of topics including pharmaceutical research and development processes.
AXON: 15.28 (+0.14)
Axovant Sciences to Present at Upcoming Investor Conferences
PR Newswire - Mon May 09, 3:00PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
AXON: 15.28 (+0.14)
Leigh Steinberg Joins Retired NFL Players in Highlighting Need for Greater Participation in Alzheimer's Clinical Trials
PR Newswire - Tue Apr 26, 6:30AM CDT
Leigh Steinberg, the legendary sports agent and inspiration for the film "Jerry Maguire," is joining retired NFL players in calling attention to the need for greater participation in Alzheimer's clinical trials.
AXON: 15.28 (+0.14)
Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016
PR Newswire - Tue Apr 19, 6:30AM CDT
Axovant Sciences Ltd. (NYSE: AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation."
AXON: 15.28 (+0.14)
Retired NFL Players Call for Greater Participation in Alzheimer's Clinical Trials as Ambassadors at Educational Events, Memory Screenings in U.S., Canada
PR Newswire - Mon Apr 18, 6:30AM CDT
"Huddle Up for New Alzheimer's Treatments" Campaign Adds Joe Rose, Joey Harrington, Ron Pitts, Christian Fauria, Steve Tasker to Line-Up with Solomon Wilcots
AXON: 15.28 (+0.14)
Axovant reports 3Q loss
Automated Insights - Tue Feb 09, 5:36PM CST
HAMILTON, Bermuda (AP) _ Axovant Sciences Ltd. (AXON) on Tuesday reported a loss of $63.4 million in its fiscal third quarter.
AXON: 15.28 (+0.14)
Axovant Sciences Announces Launch of First-in-Class Clinical Programs for Lewy Body Dementia and Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2015
PR Newswire - Tue Feb 09, 3:15PM CST
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter. In addition, the Company reported financial results for the third fiscal quarter and nine months ended December 31, 2015.
AXON: 15.28 (+0.14)
Alzheimer's Disease - Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwvj4d/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Alzheimer's Disease Overview - Therapeutics Development - Pipeline Products for Alzheimer's Disease - Overview - Pipeline Products for Alzheimer's Disease - Comparative Analysis - Alzheimer's Disease - Therapeutics under Development by Companies - Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes - Alzheimer's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Alzheimer's Disease - Products under Development by Companies - Alzheimer's Disease - Products under Investigation by Universities/Institutes - Alzheimer's Disease - Companies Involved in Therapeutics Development(Partial List) - AB Science SA - AbbVie Inc. - AC Immune SA - Acelot, Inc. - Actinogen Limited - Acumen Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Aequus Pharmaceuticals Inc. - AFFiRiS AG - Alector LLC - Alkermes Plc - ALSP, Inc. - Alzhyme Pty Ltd - Alzinova AB - AlzProtect SAS - Amarantus Bioscience Holdings, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Aphios Corporation - Apodemus AB - Applied Research using OMIC Sciences, S.L. - Araclon Biotech, S.L. - Archer Pharmaceuticals, Inc. - ArmaGen,Inc. - Artery Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Ausio Pharmaceuticals, LLC - Avergen Ltd - Avineuro Pharmaceuticals, Inc. - Axerion Therapeutics, Inc. - Axon Neuroscience SE - Axovant Sciences Ltd. For more information visit http://www.researchandmarkets.com/research/xwvj4d/alzheimers
AXON: 15.28 (+0.14), AVXL: 3.11 (-0.17), AZN: 33.97 (-0.31), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), ALKS: 49.58 (-1.42)
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
Arpita Dutt - Zacks Investment Research - Wed Feb 03, 7:28AM CST
It was all about earnings last week though growing concerns regarding the spread of the Zika virus put some companies in the spotlight.
AXON: 15.28 (+0.14), BIIB: 312.58 (-2.23), INCY: 88.98 (-0.29), NLNK: 12.87 (+0.86), XON: 27.41 (-0.63), ABBV: 64.98 (-0.10), REGN: 410.39 (+2.38)
Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease
PR Newswire - Wed Sep 21, 7:00AM CDT
Memory evaluations are critical to the early diagnosis and effective treatment of people with Alzheimer's disease, according to Dr. Gary Small, director of geriatric psychiatry at UCLA's Semel Institute for Neuroscience and Human Behavior.
AXON: 15.28 (+0.14)
Axovant Sciences to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Sep 06, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Morgan Stanley Global Healthcare Conference on September 13 at 5:15 p.m. EDT.
AXON: 15.28 (+0.14), MS: 31.91 (-0.33)
Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Baird 2016 Global Healthcare Conference on September 7 at 10:50 a.m. EDT.
AXON: 15.28 (+0.14)
Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.28 (+0.14), GSK: 43.42 (-0.16)
Axovant Sciences Announces 2015 Fiscal Year-End Financial Results and Corporate Updates
PR Newswire - Mon Jun 06, 7:00AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today reported financial results for the fourth fiscal quarter and twelve months ended March 31, 2016.
AXON: 15.28 (+0.14)
Global Lewy Body Dementia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Axovant Sciences, BioArctic Neuroscience, Immungenetics - Research and Markets
BusinessWire - Mon May 16, 10:43AM CDT
Research and Markets has announced the addition of the "Lewy body Dementia - Pipeline Review, H1 2016" report to their offering.
AXON: 15.28 (+0.14)
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 15.28 (+0.14), BMRN: 97.40 (-0.05), PFE: 34.26 (+0.11)
Should You Buy Axovant Sciences (AXON) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:35AM CDT
Axovant Sciences (AXON) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
AXON: 15.28 (+0.14)
Drug Stocks Reporting Earnings on May 17: AXON & FWP
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:31AM CDT
Quite a few beats and some misses. That's how the first-quarter scorecard cycle looks like as the earnings season nears its end for 10 of the 16 Zacks sectors.
AXON: 15.28 (+0.14), ABT: 42.19 (-0.03), JNJ: 118.81 (-0.65), FWP: 20.21 (+0.26), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), NVS: 81.48 (-0.55)
Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors
PR Newswire - Fri May 13, 5:59AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced Gary P. Pisano has joined its Board of Directors and will also serve as a member of the Board's Audit Committee. Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School and has been on the Harvard faculty since 1988. His work has focused on a wide range of topics including pharmaceutical research and development processes.
AXON: 15.28 (+0.14)
Axovant Sciences to Present at Upcoming Investor Conferences
PR Newswire - Mon May 09, 3:00PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
AXON: 15.28 (+0.14)
Leigh Steinberg Joins Retired NFL Players in Highlighting Need for Greater Participation in Alzheimer's Clinical Trials
PR Newswire - Tue Apr 26, 6:30AM CDT
Leigh Steinberg, the legendary sports agent and inspiration for the film "Jerry Maguire," is joining retired NFL players in calling attention to the need for greater participation in Alzheimer's clinical trials.
AXON: 15.28 (+0.14)
Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016
PR Newswire - Tue Apr 19, 6:30AM CDT
Axovant Sciences Ltd. (NYSE: AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation."
AXON: 15.28 (+0.14)
Retired NFL Players Call for Greater Participation in Alzheimer's Clinical Trials as Ambassadors at Educational Events, Memory Screenings in U.S., Canada
PR Newswire - Mon Apr 18, 6:30AM CDT
"Huddle Up for New Alzheimer's Treatments" Campaign Adds Joe Rose, Joey Harrington, Ron Pitts, Christian Fauria, Steve Tasker to Line-Up with Solomon Wilcots
AXON: 15.28 (+0.14)
Axovant reports 3Q loss
Automated Insights - Tue Feb 09, 5:36PM CST
HAMILTON, Bermuda (AP) _ Axovant Sciences Ltd. (AXON) on Tuesday reported a loss of $63.4 million in its fiscal third quarter.
AXON: 15.28 (+0.14)
Axovant Sciences Announces Launch of First-in-Class Clinical Programs for Lewy Body Dementia and Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2015
PR Newswire - Tue Feb 09, 3:15PM CST
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter. In addition, the Company reported financial results for the third fiscal quarter and nine months ended December 31, 2015.
AXON: 15.28 (+0.14)
Alzheimer's Disease - Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwvj4d/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Alzheimer's Disease Overview - Therapeutics Development - Pipeline Products for Alzheimer's Disease - Overview - Pipeline Products for Alzheimer's Disease - Comparative Analysis - Alzheimer's Disease - Therapeutics under Development by Companies - Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes - Alzheimer's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Alzheimer's Disease - Products under Development by Companies - Alzheimer's Disease - Products under Investigation by Universities/Institutes - Alzheimer's Disease - Companies Involved in Therapeutics Development(Partial List) - AB Science SA - AbbVie Inc. - AC Immune SA - Acelot, Inc. - Actinogen Limited - Acumen Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Aequus Pharmaceuticals Inc. - AFFiRiS AG - Alector LLC - Alkermes Plc - ALSP, Inc. - Alzhyme Pty Ltd - Alzinova AB - AlzProtect SAS - Amarantus Bioscience Holdings, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Aphios Corporation - Apodemus AB - Applied Research using OMIC Sciences, S.L. - Araclon Biotech, S.L. - Archer Pharmaceuticals, Inc. - ArmaGen,Inc. - Artery Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Ausio Pharmaceuticals, LLC - Avergen Ltd - Avineuro Pharmaceuticals, Inc. - Axerion Therapeutics, Inc. - Axon Neuroscience SE - Axovant Sciences Ltd. For more information visit http://www.researchandmarkets.com/research/xwvj4d/alzheimers
AXON: 15.28 (+0.14), AVXL: 3.11 (-0.17), AZN: 33.97 (-0.31), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), ALKS: 49.58 (-1.42)
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
Arpita Dutt - Zacks Investment Research - Wed Feb 03, 7:28AM CST
It was all about earnings last week though growing concerns regarding the spread of the Zika virus put some companies in the spotlight.
AXON: 15.28 (+0.14), BIIB: 312.58 (-2.23), INCY: 88.98 (-0.29), NLNK: 12.87 (+0.86), XON: 27.41 (-0.63), ABBV: 64.98 (-0.10), REGN: 410.39 (+2.38)
(0)
(0)